ClinicalTrials.gg
Active, not recruitingNCT05799872Updated Oct 27, 2026

Neuroscience-informed Treatment to Remotely Target Reward Mechanisms in Post-acute Anorexia Nervosa

An interventional study of Positive Affect Treatment for Anorexia Nervosa (PAT-AN): and Psychoeducational and Behavioral Therapy (PBT) in Anorexia Nervosa, sponsored by Virginia Commonwealth University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Virginia Commonwealth University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 27, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 174 studies in Anorexia Nervosa with a site in United States — 36 open to participants now, 45 under way, none of them phase 3. Anorexia Nervosa · United States.

Enrollment
41st of 143
80 · median 40
Started
2023
with 13 others
No phase
94 of 174
24 open now
Primary completion
2026-09
later than 8 of 44 live
Registered
135th of 174
by date

Among the 174 studies in Anorexia Nervosa with a site in United States, this one is the 41st largest by enrollment of the 143 interventional ones that give a count, is one of 14 that started in 2023, is one of 94 with no phase, reaches primary completion later than 8 of the 44 other live ones, and was the 135th registered.

Anorexia Nervosa

471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

36 of the 174 studies in Anorexia Nervosa with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 174 studies in Anorexia Nervosa with a site in United States, or all of them as a file.
02

Study summary

The investigators will recruit individuals with broadly-defined AN (n = 80) who are currently in or have recently participated in higher-level eating disorder treatment (e.g., residential, partial hospitalization/day treatment, intensive outpatient treatment). Interested participants will sign consent, complete eligibility assessments, and will be randomized to receive Positive Affect Treatment for Anorexia Nervosa (PAT-AN) or Psychoeducation and Behavioral Therapy (PBT) through teletherapy shortly following discharge from higher level of care. Participants can participate in most other forms of outpatient treatment while receiving the research intervention. Participants will engage in 24 weeks of PAT-AN or PBT starting in the first 3 months post-discharge. At each session, the investigators will complete brief measures assessing treatment acceptability, affect, and eating disorder symptoms. Participants will also complete an assessment battery of self-report, EMA, and neurocognitive measures evaluating primary outcomes (BMI; eating disorder symptoms), secondary outcomes (depression, anxiety, and suicidality), and presumed treatment mechanisms at baseline, end of treatment (EOT), and 3-month follow-up (FU). All assessments will be remotely delivered via HIPAA-compliant platforms.

03

Conditions studied

  • Anorexia Nervosa

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age > or = 18 years old
  2. Ability to read and speak in English
  3. diagnosis of AN or atypical AN at admission to higher-level care
  4. In higher-level care discharging to outpatient care or discharged to outpatient care within the past 3 months
  5. Current > or = 18.5 kg/m2 (or will be by time of discharge)
  6. BMI increase of > or = 0.5 kg/m2 while in higher-level care
  7. Ability to designate and sign a release of information for a primary physical or mental health provider for study duration
  8. Willingness to participate in weekly assessments (e.g., weight monitoring) and audio or video recording of study therapy sessions for study duration
  9. Access to a smartphone and/or computer permitting engagement in remote therapy and assessment.

Exclusion criteria

Exclusion Criteria:

  1. Medical instability for outpatient care;
  2. Pregnancy
  3. Lifetime primary psychotic or bipolar-I disorder
  4. Current DSM-5 substance use disorder
  5. Enrollment in outpatient therapy with highly overlapping content to PAT-AN
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Positive Affect Treatment for Anorexia Nervosa (PAT-AN):

    Behavioral: Positive Affect Treatment for Anorexia Nervosa (PAT-AN):

  • Active comparator
    Psychoeducational and Behavioral Therapy (PBT):

    Behavioral: Psychoeducational and Behavioral Therapy (PBT)

Interventions

  • BehavioralPositive Affect Treatment for Anorexia Nervosa (PAT-AN):

    PAT-AN is an adaptation of the cognitive-behavioral outpatient individual therapy for anhedonia (17, 68). The overarching aim of PAT-AN is to enhance reward sensitivity (reward anticipation, experiencing, and learning) to non-eating disorder experiences and to decrease or replace reward sensitivity to weight-loss experiences (26). PAT-AN includes 6 sequential modules, each designated to target specific reward sensitivity disturbances (26, 68). Homework and experiential practice during sessions are essential components of PAT-AN, and participants are provided a workbook to assist with this practice. During each session, collaborative homework review is followed by skill development and homework assignments.

  • BehavioralPsychoeducational and Behavioral Therapy (PBT)

    The comparison treatment is modeled off of educational and behavioral interventions used in prior clinical trials for AN and common elements of standard behavioral eating disorder treatments. The treatment is structured to parallel the modular format of PAT-AN.

06

What researchers measure

Primary outcomes

  1. Change in Body Mass Index (BMI) from Baseline to End of Treatment

    Objective height will be captured through guided measurement at baseline. Objective weight will be measured throughout on a blind smartscale, which will transfer weight data directly to the research team by wireless internet without providing an outward display of weight to participants. Participants will have a smartscale shipped to their home. They will measure their weight at baseline and following treatment on the scale in standard street clothes (no outer garments or shoes) while on a video call with research staff.

    Time frame: Baseline to End of treatment (week 24)

  2. Change in Eating Disorder Symptoms

    The Eating Disorder Examination (EDE) is an investigator-based interview assessing eating disorder psychopathology that will be used as the primary measure of eating disorder symptoms. The EDE has extensive psychometric data to support its reliability and validity. The EDE comprises four subscales: Restraint, Eating Concern, Shape Concern, and Weight Concern. Each question is scored by the interviewer based on frequency over the past month from 0 (symptom not present) to 6 (symptom present every day). Each subscale score is the average of all items in the subscale, while global EDE score is the average of the four subscale scores. Higher EDE scores indicate greater severity and frequency of eating disorder symptoms.

    Time frame: Baseline to End of treatment (week 24)

Secondary outcomes

  1. Change in Depressive Symptoms

    The Depression, Anxiety, and Stress Scale-21 is a self-report measure that will assess depressive symptom severity. The depression subscale consists of 7 items rated from 0 (did not apply to me at all) to 3 (applied to me very much or most of the time). Scores on the DASS-21 depression subscale range from 0 to 21, with higher scores indicating greater depressive symptom severity.

    Time frame: Baseline to End of treatment (week 24)

  2. Change in Anxiety Symptoms

    The Depression, Anxiety, and Stress Scale-21 is a self-report measure that will assess anxiety symptom severity. The anxiety subscale consists of 7 items rated from 0 (did not apply to me at all) to 3 (applied to me very much or most of the time). Scores on the DASS-21 anxiety subscale range from 0 to 21, with higher scores indicating greater anxiety symptom severity.

    Time frame: Baseline to End of treatment (week 24)

  3. Change in Suicidal Ideation

    The Columbia - Suicide Severity Rating Scale (C-SSRS) is an interview-based measure assessing the presence and intensity of suicidal ideation and the presence of suicidal behavior. The C-SSRS will be used to determine if treatment impacts suicidal ideation. Intensity of suicidal ideation is rated from 0-5, with higher scores indicating more severe suicidal ideation.

    Time frame: Baseline to End of treatment (week 24)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Final dataset will include information from self-report questionnaires, clinician-guided interviews, physical assessments, ecological momentary assessment, and neurocognitive tasks. Data will be de-identified and consistent with NDA regulations. Data will be shared via the National Database for Clinical Trials Related to Mental Illness (NDCT) in the NIMH Data Archive (NDA). Established by NIMH, and supported by other Institutes of NIH, the NDA is a secure informatics platform for scientific collaboration and data-sharing. All data will be collected from subjects who have broadly consented to share their data for research use or who have consented to share their data for research, with data use limitations. All de-identified data resulting from this project will be submitted to the NDA at the item level and subject level along with appropriate supporting documentation to enable efficient use of the data.

Supporting information: Informed consent form

Time frame: Descriptive/raw research data will be made available for access to other researchers within four (4) months after submission.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Sep 2026, 33 months.

Of 149 non-industry interventional studies with no phase under Anorexia Nervosa, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's 33 months is below that.

Counting every sponsor, half of 149 studies reached it within 43 months; a quarter within 24 and three quarters within 63.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Aug 2026 → Sep 2026 and completion Aug 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2023
First posted
Apr 5, 2023
StartActual
Dec 6, 2023
Primary completionActual
Sep 17, 2026was Aug 2026
CompletionEst.
Aug 31, 2027was Aug 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 27, 2026
Primary completion
Aug 31, 2026→Sep 17, 2026 (actual)
Oct 27, 2026
Study completion
Aug 31, 2026→Aug 31, 2027
Oct 27, 2026
Enrollment
90 (estimated)→80 (actual)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Recruiting→Active, not recruiting
    Primary completion Aug 31, 2026→Sep 17, 2026 (now actual)
    Study completion Aug 31, 2026→Aug 31, 2027
    Enrollment 90 (estimated)→80 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05799872
Responsible party
Sponsor
First posted
Apr 5, 2023
Start date
Dec 6, 2023
Primary completion
Sep 17, 2026
Completion
Aug 31, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Ann Haynos, PhD
principal investigator · Principal Investigator

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion